SCHEMBL452059

SCHEMBL452059

CCCCOC(=O)OC(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
LMNA P02545 3/20 0.48
ATM Q13315 1/20 0.48
TSHR P16473 5/20 0.45
HPGD P15428 2/20 0.45
HCAR2 Q8TDS4 1/20 0.42
NAAA Q02083 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
EPHX1 P07099 1/20 0.39
ESR1 P03372 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10087932 0.94 LMNA (0.52) ALDH1A1LMNAATMTSHRHCAR2
SCHEMBL6897000 0.92 LMNA (0.55) ALDH1A1LMNATSHRHCAR2NAAA
SCHEMBL27482658 0.90 ALDH1A1 (0.47) ALDH1A1LMNAATMTSHRHPGD
SCHEMBL28887013 0.90 ALDH1A1 (0.47) ALDH1A1LMNAATMTSHRHPGD
SCHEMBL11877269 0.90 ALDH1A1 (0.47) ALDH1A1LMNAATMTSHRHPGD
SCHEMBL14715673 0.89 TSHR (0.42) ALDH1A1LMNAATMTSHRHPGD
SCHEMBL14891234 0.87 ALDH1A1 (0.52) ALDH1A1LMNAATMTSHRHPGD
SCHEMBL577735 0.86 LMNA (0.42) ALDH1A1LMNATSHRHCAR2TDP1
SCHEMBL7665438 0.86 ALDH1A1 (0.40) ALDH1A1LMNAATMTSHRHPGD
SCHEMBL6008417 0.85 ALDH1A1 (0.50) ALDH1A1LMNAATMTSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5412003-A Filled with hollow glass microspheres with reduced alkalinity to improve water resistance, automobile panels TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-02 US claimed
WO-2025119860-A1 LIQUID AGROCHEMICAL FORMULATIONS COMPRISING FLUPYRADIFURONE BAYER AKTIENGESELLSCHAFT (DE) 2025-06-12 WO disclosed
EP-3771014-B1 NONAQUEOUS ELECTROLYTE SOLUTION FOR POWER STORAGE DEVICES TOMIYAMA PURE CHEMICAL INDUSTRIES LTD (JP) 2025-03-05 EP disclosed
US-12155037-B2 Nonaqueous electrolyte solution for power storage devices TOMIYAMA PURE CHEMICAL INDUSTRIES, LTD. (JP) 2024-11-26 US disclosed
US-12107226-B2 Electrolyte for power storage devices and nonaqueous electrolyte solution TOMIYAMA PURE CHEMICAL INDUSTRIES, LTD. (JP) 2024-10-01 US disclosed
US-20240131180-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2024-04-25 US disclosed
EP-4025253-B1 DRUG ANTIBODY CONJUGATES PHARMA MAR SA (ES) 2024-03-20 EP disclosed
US-20240088444-A1 ELECTROLYTE FOR POWER STORAGE DEVICES AND NONAQUEOUS ELECTROLYTE SOLUTION TOMIYAMA PURE CHEMICAL INDUSTRIES, LTD. (JP) 2024-03-14 US disclosed
CN-114615999-B Drug antibody conjugates 法马马有限公司 2024-03-08 CN disclosed
EP-4318629-A1 PRIMER FOR POWER STORAGE DEVICE ELECTRODES, COMPOSITION FOR FORMING PRIMER LAYER, ELECTRODE FOR POWER STORAGE DEVICES, AND SECONDARY BATTERY AGC INC. (JP) 2024-02-07 EP disclosed
US-5412003-A Filled with hollow glass microspheres with reduced alkalinity to improve water resistance, automobile panels TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-02 US disclosed
US-5395865-A Storage stable compositions containing a polymerization inhibitor TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-03-07 US disclosed
EP-0628559-A1 Pyrimidine compounds and their use as pharmaceuticals Beiersdorf-Lilly GmbH (DE) 1994-12-14 EP disclosed
EP-0603001-A1 Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease SANKYO COMPANY LIMITED (JP) 1994-06-22 EP disclosed
EP-0573218-A2 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use SANKYO COMPANY LIMITED (JP) 1993-12-08 EP disclosed
EP-0567271-A2 Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses SANKYO COMPANY LIMITED (JP) 1993-10-27 EP disclosed
EP-0552789-A1 Unsaturated polyester resin compositions, molding materials, and molded products TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-07-28 EP disclosed
EP-0545912-A2 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use Sankyo Company Limited (JP) 1993-06-09 EP disclosed
EP-0542494-A1 Unsaturated polyester compositions, molding materials and molded products TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-05-19 EP disclosed
EP-0503785-A1 1-Biphenylimidazole derivatives, their preparation and their therapeutic use Sankyo Company Limited (JP) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240131180-A1 DRUG ANTIBODY CONJUGATES STT3B, STT3A, TTL ALDH1A1 785/4885LMNA 1254/4885ATM 3058/4885
US-12155037-B2 Nonaqueous electrolyte solution for power storage devices AQP1, NCS1, SLC9A1 ALDH1A1 1681/4885LMNA 2823/4885ATM 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.